Targeting ferroptosis for overcoming chemoresistance in digestive tract tumors

The global burden of digestive tract tumors is profound, with these cancers accounting for nearly half of all malignant tumors worldwide.

Risk Adjusted Net Present Value: What is the current valuation of Roivant Sciences’s Brepocitinib tosylate

The revenue for Brepocitinib tosylate is expected to reach an annual total of $256 mn by 2035 in the US based off GlobalData’s Expiry Model.

May 16, 2024

Study reveals how neighboring synapses compete for plasticity resources

Nerve cells in the brain receive thousands of synaptic signals via their “antenna”, the so-called dendritic branch.

September 2, 2024

177Lu-PNT6555 by POINT Biopharma Global for Solid Tumor: Likelihood of Approval

Share this article GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug

December 26, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.